Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Aptamer-based surface-enhanced resonance Raman scattering assay on a paper fluidic platform for detection of cardiac troponin I

J Biomed Opt. 2020; 
Dandan Tu, Allison Holderby, Gerard L Coté
Products/Services Used Details Operation
Gene Synthesis … cTnI. JBO_25_9_097001_f001.png. 2.2. Materials and Instruments. cTnI was purchased from GenScript (Piscataway, New Jersey, USA). The sequence of aptamers for the cTnI assay was reported in previous journal papers. 39 … Get A Quote

摘要

conclusions: Cardiac troponin I (cTnI) is a primary biomarker for diagnosis of myocardial infarction (MI). In contrast to central laboratory tests for cTnI, point-of-care (POC) testing has the advantage of providing results when the patient is first encountered, which helps high-risk patients to be treated more rapidly and low-risk patients to be released in a timely fashion. A paper fluidic platform is good for POC testing because the paper is abundant, low cost, and disposable. However, current cTnI assays on paper platforms use antibodies as the recognition element, which has limitations due to the high cost of production and antibody stability issues at the POC. objective: To develop an aptamer-based assay ... More

关键词

aptamer sensor, myocardial infarction, point-of-care testing, surface-enhanced Raman spectroscopy
XML 地图